SAN MATEO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX), a biopharmaceutical company focused on developing and
commercializing novel pain management therapies, announced today that
Anthony DiTonno, Chief Executive Officer, is scheduled to participate in a
workshop focused on pain management at the 10th Annual BIO CEO & Investor
Conference in New York, NY on Monday, February 11, 2008.
Event: 10th Annual BIO CEO & Investor Conference
Date: Monday, February 11, 2008
Time: 9:30 a.m. ET
Place: The Waldorf-Astoria Hotel, Basildon Room, 3rd Floor
301 Park Avenue, New York 10022
A live audio Web cast of the workshop can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1476 798
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements concerning future
presentations by NeurogesX and the expected benefits of NeurogesX'
potential products, including its lead product candidate NGX-4010. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, past results of clinical trials may not be
indicative of future clinical trials results; NeurogesX' product candidate
may have unexpected adverse side effects or inadequate therapeutic
efficacy; positive results in clinical trials may not be sufficient to
obtain FDA or European regulatory approval; physician or patient reluctance
to use NGX-4010, if approved, or the inability of physicians to obtain
sufficient reimbursement for such procedures; potential alternative
therapies; maintaining adequate patent or trade secret protection without
violating the intellectual property rights of others; and other
difficulties or delays in clinical development, obtaining regulatory
approval, market acceptance and commercialization of NGX-4010 and the
advantages of NGX-4010 over other pain therapies. For further information
regarding these and other risks related to NeurogesX' business, investors
should consult NeurogesX' filings with the Securities and Exchange
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved